Back to results
US 2022/0017638 A1Published application
Method of treating atherosclerosis
AssigneeCSL Limited
InventorsCon PANOUSIS, Karlheinz PETER, Hamid HOSSEINI, Yung-Chih CHEN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.
Claims12
A method of treating atherosclerosis in a subject, comprising administering to the subject an effective amount of an anti-Factor XII (FXII) antibody or antigen binding fragment thereof comprising:
- (i) a VH comprising:
- (a) a sequence set forth in SEQ ID NO:
- 6;
- or
- (b) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 8;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 10;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 12;
- or
- (c) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 8;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 9;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 11;
- and/or
- (ii) a VL comprising:
- (a) a sequence set forth in SEQ ID NO:
- 7;
- or
- (b) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 13;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 14;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 16;
- or
- (c) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 13;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 14;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 15.
32 more elements
A kit for use in the treatment or prevention of atherosclerosis in a subject, comprising:
- (a) an anti-FXII antibody or antigen binding fragment thereof comprising
- (i) a VH comprising:
- (A) a sequence set forth in SEQ ID NO:
- 6;
- or
- (B) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 8;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 10;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 12;
- or
- (C) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 8;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 9;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 11;
- and/or
- (ii) a VL comprising:
- (A) a sequence set forth in SEQ ID NO:
- 7;
- or
- (B) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 13;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 14;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 16;
- or
- (c) a CDR1 comprising a sequence set forth in SEQ ID NO:
- 13;
- a CDR2 comprising a sequence set forth in SEQ ID NO:
- 14;
- and a CDR3 comprising a sequence set forth in SEQ ID NO:
- 15;
- (b) instructions for using the kit in treating or preventing atherosclerosis in the subject;
- and
- (c) optionally, at least one further therapeutically active compound or drug.
36 more elements
An anti-Factor XII (FXII) antibody or antigen binding fragment thereof, wherein the anti-FXII antibody comprises:
- (i) a VH comprising a sequence set forth in SEQ ID NO:
- 18 and a VL comprising a sequence set forth in SEQ ID NO:
- 19;
- or
- (ii) a heavy chain comprising a sequence set forth in SEQ ID NO:
- 20 and a light chain comprising a sequence set forth in SEQ ID NO:
- 21.
4 more elements
Dependencies are inferred from the claim text.